Literature DB >> 4093204

Serum concentrations of mebendazole in patients with hydatid disease.

A Bekhti.   

Abstract

Mebendazole was administered to 22 patients, 17 of whom had developing or cured hydatid cysts, and to 5 volunteers. Then, at regular intervals, it was titrated by radioimmunoassay in the serum for 24 hours. Serum levels after the intake of 1 gram were perceptible on an empty stomach; they were higher when the drug was taken with a rich meal, but the difference was not statistically significant. The administration of increasing therapeutic doses (3, 4.5, 6 and 12 g a day) led to a concomitant increase of the average serum levels of mebendazole; concentrations varied between a minimum of 7.6 ng/ml and a maximum of 483 ng/ml. The difference between the various average concentrations was only significant after 8 hours when increasing from 3 to 6 g a day. The absence of a significant difference for the other average concentrations was due to the large interindividual variations. However, analysis of the individual results shows an increase of the serum concentrations parallel with that of the dose in 10 out of 12 patients. The effect of the dose seems to vary with the patient and the dose received. Blood samples taken 2 hours after each of the 3 daily drug intakes could give more information as to the serum concentrations susceptible to influence the parasite. The drug's half life, lying between 3.3 and 11.5 hours in 5 patients, is longer in case of major hepatic dysfunction, due to established hepatopathy. During the monitoring of 7 patients, the average serum levels were comparable with or higher than the initial concentration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4093204

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  8 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

3.  Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.

Authors:  Andrew R Larsen; Ren-Yuan Bai; Jon H Chung; Alexandra Borodovsky; Charles M Rudin; Gregory J Riggins; Fred Bunz
Journal:  Mol Cancer Ther       Date:  2014-11-05       Impact factor: 6.261

4.  Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts.

Authors:  A Bekhti; J Pirotte
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

5.  [Chemotherapy of alveolar echinococcosis with benzimidazoles. A prospective long-term study].

Authors:  S Reuter; W Kratzer; S Kurz; N Wellinghausen; P Kern
Journal:  Med Klin (Munich)       Date:  1998-08-15

6.  Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.

Authors:  Vijay M Patil; Arti Bhelekar; Nandini Menon; Atanu Bhattacharjee; Vijai Simha; Ram Abhinav; Anuja Abhyankar; Epari Sridhar; Abhishek Mahajan; Ameya D Puranik; Nilendu Purandare; Amit Janu; Ankita Ahuja; Rahul Krishnatry; Tejpal Gupta; Rakesh Jalali
Journal:  Cancer Med       Date:  2020-05-13       Impact factor: 4.452

Review 7.  Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature.

Authors:  Andrea Emanuele Guerini; Luca Triggiani; Marta Maddalo; Marco Lorenzo Bonù; Francesco Frassine; Anna Baiguini; Alessandro Alghisi; Davide Tomasini; Paolo Borghetti; Nadia Pasinetti; Roberto Bresciani; Stefano Maria Magrini; Michela Buglione
Journal:  Cancers (Basel)       Date:  2019-08-31       Impact factor: 6.639

8.  Revisiting the Effect of Pharmaceuticals on Transmission Stage Formation in the Malaria Parasite Plasmodium falciparum.

Authors:  Basil T Thommen; Armin Passecker; Tamara Buser; Eva Hitz; Till S Voss; Nicolas M B Brancucci
Journal:  Front Cell Infect Microbiol       Date:  2022-02-11       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.